Global Pancreatic Cancer Market - Overview
Pancreatic Cancer is an enlarged tumor caused by malignant cells in the tissues of the pancreas. The pancreas are organ situated behind the stomach. Pancreatic cancer can be caused by smoking, drinking alcohol, radiotherapy in the past, genetic factors, age, inflammation of the pancreas, obesity, and diabetes mellitus. According to Cancer Research UK, 7 out of 10 cases of chronic pancreatitis are due to heavy drinking habits.
Free Sample Report: https://www.marketresearchfuture.com/sample_request/1638
Rising rates in tobacco consumption, increasing cigarette smokers are likely to enhance the growth of pancreatic cancer market. Additionally, rising prevalence of cancer, increase in intake of alcohol, growing obesity rates, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level.
However high costs, and the side effects related to the treatment of pancreatic cancer are likely to hamper the growth of pancreatic cancer market.
KEY MARKET PLAYERS
There are various market players operating in the global pancreatic cancer market. PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.
Celgene Corporation
Founded in 1980, and headquartered at US, Celgene Corporation is a biopharmaceutical company aimed in the detection and development of treatments for various cancers and inflammatory diseases. Celgene Corporation has its presence all over the world. The firm has focused on various inorganic and organic growth strategies to enhance its services and increase its patient base. For instance in the year 2015, Celgene Corporation received approval from European Commission (EC) for ABRAXANE, a nanotechnology therapy for the treatment of metastatic pancreatic cancer.
The firm has been focusing on improving lives of patients with pancreatic cancer. For instance in 2015, Celgene Corporation invested 30% of its revenue on research and development to produce advanced technologies to support patients with pancreatic cancer. By this approval and high research and development expenditure, the firm aims to focus on patient needs and increase its customer base.
Novartis AG
Founded in 1895, and headquartered in Switzerland, Novartis AG is engaged in the manufacture and development of a wide range of healthcare products. In 2016, Novartis and Pfizer collaborated to form a study on tumors driven by mutations in a gene called KRAS that causes cancer. Additionally, in 2017 Novartis and Perthera partnered to support clinical trials for lung cancer patients. This collaboration and partnership enables the firm to widen its foothold in various geographies.
Browse full report@ https://www.marketresearchfuture.com/reports/pancreatic-cancer-market-1638
Regional Analysis:
Geographically, the pancreatic cancer market is segmented into four key regions: the Americas, Europe, Asia Pacific, and Middle East & Africa.The Americas is further segmented into North America and South America. And North America is segmented into the U.S. and Canada. Globally, the U.S. is the largest market for pancreatic cancer owing to rising prevalence of cancer, increasing consumption of alcohol, increase in per capita R&D spending, along with rise in demand for new and advanced products and techniques.